MX2022012592A - Construcciones de citocinas activables y composiciones y metodos relacionados. - Google Patents

Construcciones de citocinas activables y composiciones y metodos relacionados.

Info

Publication number
MX2022012592A
MX2022012592A MX2022012592A MX2022012592A MX2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A
Authority
MX
Mexico
Prior art keywords
activatable
methods
related compositions
cytokine
constructs
Prior art date
Application number
MX2022012592A
Other languages
English (en)
Inventor
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Scolan Erwan Le
Walter A Bogdanoff
Na Cai
Hsin Wang
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2022012592A publication Critical patent/MX2022012592A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

En la presente se proporcionan construcciones de citocinas activables que incluyen: (a) una primera construcción de monómero que comprende una primera proteína de citocina madura (CP1), un primer resto escindible (CM1) y un primer dominio de dimerización (DD1), en donde el CM1 está ubicado entre el CP1 y el DD1; y (b) una segunda construcción de monómero que comprende una segunda proteína de citocina madura (CP2), un segundo resto escindible (CM2) y un segundo dominio de dimerización (DD2), donde el CM2 está ubicado entre el CP2 y el DD2, donde: el CM1 y el CM2 funcionan como sustrato para una proteasa; el DD1 y el DD2 se unen entre sí; y donde la ACC está caracterizada por una reducción en al menos una actividad del CP1 y/o CP2 en comparación con un nivel de control de al menos una actividad del CP1 y/o CP2.
MX2022012592A 2020-04-10 2021-04-09 Construcciones de citocinas activables y composiciones y metodos relacionados. MX2022012592A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063008542P 2020-04-10 2020-04-10
US202163161889P 2021-03-16 2021-03-16
US202163164849P 2021-03-23 2021-03-23
PCT/US2021/026675 WO2021207669A1 (en) 2020-04-10 2021-04-09 Activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2022012592A true MX2022012592A (es) 2022-12-07

Family

ID=75747127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012592A MX2022012592A (es) 2020-04-10 2021-04-09 Construcciones de citocinas activables y composiciones y metodos relacionados.

Country Status (11)

Country Link
US (2) US11365233B2 (es)
EP (1) EP4133085A1 (es)
JP (1) JP2023520922A (es)
KR (1) KR20220167295A (es)
CN (1) CN115667523A (es)
AU (1) AU2021254283A1 (es)
BR (1) BR112022020440A2 (es)
CA (1) CA3174786A1 (es)
IL (1) IL297225A (es)
MX (1) MX2022012592A (es)
WO (1) WO2021207669A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304958A (zh) * 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法
WO2023034825A1 (en) 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
CA3233663A1 (en) * 2021-10-08 2023-04-13 Na CAI Activatable cytokine constructs and related compositions and methods
US20240116997A1 (en) 2022-02-23 2024-04-11 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023168403A2 (en) * 2022-03-03 2023-09-07 The Trustees Of The University Of Pennsylvania Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism
WO2023183888A1 (en) 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023183923A1 (en) 2022-03-25 2023-09-28 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023192606A2 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030843A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030847A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
US20240067691A1 (en) * 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
ATE513563T1 (de) 2000-10-09 2011-07-15 Isis Innovation Therapeutische und toleranz-induzierende antikörper
GB0100551D0 (en) * 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US20060269516A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IgG fusion
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US20100297081A1 (en) 2007-12-18 2010-11-25 Huang Yanshan Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester CYTOKINES ACTIVATED BY PROTEASES
WO2012072815A1 (en) 2010-12-03 2012-06-07 Adamed Sp. Z O.O. Anticancer fusion protein
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2014324884B2 (en) 2013-09-25 2020-03-26 Cytomx Therapeutics, Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015116933A2 (en) 2014-01-31 2015-08-06 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
CA3067539A1 (en) 2017-06-20 2018-12-27 The Board Of Regents Of The University Of Texas System Interferon prodrug for the treatment of cancer
EP3706803A4 (en) 2017-11-08 2021-08-04 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. CONJUGATES OF BIOMOLECULES AND THEIR USES
TWI800552B (zh) 2017-11-10 2023-05-01 新加坡科技研究局 介白素2受體β(IL2Rβ)/共同γ鏈抗體
EP3727146A4 (en) 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
EP3762406A2 (en) 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP2021523741A (ja) 2018-05-14 2021-09-09 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
ES2955537T3 (es) 2018-06-21 2023-12-04 Tgw Logistics Group Gmbh Sistema y procedimiento de almacenamiento y preparación de pedidos para recoger mercancías de una bolsa colgante y otro dispositivo auxiliar de carga
KR20210038548A (ko) 2018-06-22 2021-04-07 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
US20210221864A1 (en) 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
BR112021005665A2 (pt) 2018-09-28 2021-06-22 Pierre Fabre Medicament novas imunocitocinas para o tratamento de câncer
PE20211279A1 (es) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fc
WO2020118109A2 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP2022513888A (ja) 2018-12-14 2022-02-09 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－１５組成物およびその使用方法
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
KR20220012256A (ko) 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
JPWO2020246567A1 (es) 2019-06-05 2020-12-10
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP3997115A4 (en) 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
CN114466657A (zh) 2019-07-25 2022-05-10 芝加哥大学 包括蛋白酶激活治疗剂的组合物和方法
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
US20220306714A1 (en) 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
JP2023503868A (ja) 2019-12-05 2023-02-01 イミューン ターゲティング インク． インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法
WO2021119516A1 (en) 2019-12-13 2021-06-17 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
CA3164522A1 (en) 2020-01-15 2021-07-22 Phillip S. KIM Cytokine prodrugs comprising a cleavable linker
KR20230024252A (ko) 2020-03-23 2023-02-20 자임워크스 비씨 인코포레이티드 차폐된 il12 융합 단백질 및 이의 사용 방법
US20230226202A1 (en) 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
BR112022019689A2 (pt) 2020-04-01 2022-12-20 Xilio Dev Inc Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer
CN115734806A (zh) 2020-04-01 2023-03-03 西里欧发展公司 掩蔽的il-12细胞因子和其切割产物
WO2021202673A2 (en) 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-15 cytokines and their cleavage products
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
JP2023526428A (ja) 2020-05-19 2023-06-21 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なｉｌ－１２ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
KR20220167295A (ko) 2022-12-20
AU2021254283A1 (en) 2022-11-10
US11365233B2 (en) 2022-06-21
CN115667523A (zh) 2023-01-31
US20210317177A1 (en) 2021-10-14
US20220402990A1 (en) 2022-12-22
CA3174786A1 (en) 2021-10-14
JP2023520922A (ja) 2023-05-22
BR112022020440A2 (pt) 2022-12-27
EP4133085A1 (en) 2023-02-15
WO2021207669A1 (en) 2021-10-14
IL297225A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2022012592A (es) Construcciones de citocinas activables y composiciones y metodos relacionados.
US9385662B2 (en) Supply modulator
WO2022197764A3 (en) Masked activatable cytokine constructs and related compositions and methods
KR101145666B1 (ko) 고주파용 3-스테이지 질화 갈륨계 고전자 이동도 트랜지스터(ＧａＮ ＨＥＭＴ) 도허티 전력증폭기
CN102064774B (zh) 一种功率放大电路实现方法及功率放大装置
CN102427332A (zh) Doherty功率放大器及提高其功放效率的方法、设备
CN103812454A (zh) 包络追踪系统的校准方法及装置
CN105932970A (zh) 包络跟踪的Doherty功率放大器
CN102170268A (zh) 功率放大装置及功放电路
TW200726046A (en) Switched converter with variable peak current and variable off-time control
TW200518535A (en) High performance modulator architecture for the outphasing rf amplifier
CN102170269A (zh) 功率放大装置及功放电路
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
CN101783652A (zh) 一种易于实现的多级Doherty功放
CN102761310A (zh) 一种多合体功率放大器及其实现方法
CN102185564A (zh) 功率放大装置及功放电路
CN102185565A (zh) 功率放大装置及功放电路
AU2022360371A1 (en) Activatable cytokine constructs and combination methods
CN201499137U (zh) 功率放大器
CN201113924Y (zh) 带直流偏置的二极管双平衡混频器
CN208608971U (zh) 一种氮化镓微波集成电路脉冲调制电路
CN104836536A (zh) 一种基于负反馈的功率放大器结构
Steinbeiser et al. Doherty power amplifiers using 2nd generation HVHBT technology for high efficiency basestation applications
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
CN205545167U (zh) 双模功率放大器